Volume 21, Number 9—September 2015
Letter
Increase in Lymphadenitis Cases after Shift in BCG Vaccine Strain
Giorgi Kuchukhidze
, Ana Kasradze, Tamar Dolakidze, David Baliashvili, Tsira Merabishvili, Henry M. Blumberg, and Russell R. Kempker
, Ana Kasradze, Tamar Dolakidze, David Baliashvili, Tsira Merabishvili, Henry M. Blumberg, and Russell R. Kempker
Table
Characteristics of 23 infants with BCG lymphadenitis, Georgia, January 2012–July 2013*
| Hospital, infant no. | Characteristic† |
Treatment outcome‡ | ||||||
|---|---|---|---|---|---|---|---|---|
| Sex | Date of birth | Age at presentation, mo | Size of axillary lymph node, mm | Culture | Surgery | Drugs used | ||
| NCTLD, n = 15 | ||||||||
| 1 | F | 2012 Jan 9 | 5 | 20 | Pos | No | R, I, P | Completed |
| 2 | M | 2012 Dec 19 | 5 | 14 | ND | No | R, I, P | Completed |
| 3 | F | 2012 Jul 2 | 9 | 40 | NA | No | R, I, P | Completed |
| 4 | F | 2012 May 31 | 12 | 28 | NA | No | R, I, P | Completed |
| 5 | M | 2012 Jul 25 | 4 | 15 | NA | No | R, I, P | Computed |
| 6 | F | 2012 Aug 16 | 1 | 15 | NA | No | R, I, P | Defaulted |
| 7 | M | 2012 Feb 7 | 2 | 22 | NA | No | R, I, P | Completed |
| 8 | M | 2011 Nov 28 | 3 | 24 | NA | No | R, I, P | Defaulted |
| 9 | M | 2012 Jul 9 | 2 | 18 | NA | No | R, I, P | Defaulted |
| 10 | M | 2012 Aug 7 | 7 | 23 | NA | Yes | R, I, E | Unknown |
| 11 | M | 2012 May 10 | 4 | 56 | NA | No | R, I, P | Completed |
| 12 | M | 2012 Nov 13 | 6 | 60 | NA | No | R, I, P | Completed |
| 13 | M | 2012 Oct 1 | 2 | 11 | Pos | Yes | R, I | Completed |
| 14 | M | 2012 Feb 22 | 9 | 24 | NA | No | R, I, P, E | Completed |
| 15 | F | 2012 Feb 24 | 5 | 15 | NA | Yes | R, I, P | Complete |
| Pediatric hospital, n = 8 | ||||||||
| 1 | F | 2013 Jan 28 | 4 | 25 | ND | Yes | None | Unknown |
| 2 | M | 2012 Jun 15 | 8 | 20 | ND | Yes | None | Unknown |
| 3 | M | 2012 Mar 25 | 15 | 17 | ND | Yes | None | Unknown |
| 4 | M | 2012 Jan 28 | 6 | 21 | ND | Yes | None | Unknown |
| 5 | M | 2013 Jan 28 | 4 | 21 | ND | Yes | None | Cured |
| 6 | M | 2012 Jun 28 | 8 | 25 | ND | Yes | None | Unknown |
| 7 | M | 2013 Mar 28 | 5 | 15 | ND | No | None | Cured |
| 8 | F | 2013 Jun 8 | 1 | 17 | ND | No | None | Cured |
*BCG, bacillus Calmette-Guérin vaccine; POS, positive; E, ethambutol; I, isoniazid; P, pyrazinamide; R, rifampin; NA, not available; ND, not done; NCTLD, National Center for Tuberculosis and Lung Diseases.
†For all patients, type of BCG strain used was Danish SSI (Statens Serum Institute, Copenhagen, Denmark).
‡Defaulted is an outcome definition applied by the tuberculosis program when a patient misses treatment for 2 consecutive months and is considered lost to follow-up.
Page created: August 14, 2015
Page updated: August 14, 2015
Page reviewed: August 14, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.